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The Genetic Basis of Abdominal Aortic Aneurysms: A Review
R.M. Sandford,* M.J. Bown, N.J. London and R.D. Sayers
Vascular Surgery Group, Department of Cardiovascular Sciences, University of Leicester, UK
Introduction. The pathogenesis of abdominal aortic aneurysm (AAA) remains poorly understood, however significant
evidence has emerged in recent years to suggest a chronic inflammatory process. Observational studies have highlighted
a familial trend towards AAA development among relatives of affected individuals and it is thought that inflammatory
genes may influence an individual’s susceptibility. Conflicting reports exist over single gene versus multiple gene
inheritance patterns in addition to a collection of studies examining individual inflammatory genes. This paper reviews
the evidence for a genetic predisposition to aneurysm formation including familial and segregation studies in addition
to experimental evidence investigating specific candidate genes.
Method. Medline and Pubmed database searches were conducted using the search terms abdominal aortic aneurysm and
gene. Papers were reviewed and references manually searched for further relevant publications which were added to the
data. Papers were categorised under the headings familial, segregation and candidate gene studies.
Results. A review of 58 papers is presented under sub-headings as above. In the case of the candidate gene section, a brief
report of the functional relevance of each gene is included.
Conclusion. A summary of the evidence presented is given and the direction of future work in this field is briefly considered.
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The incidence of abdominal aortic aneurysm (AAA)
has been steadily increasing over recent years,1 with
up to 8% of men over the age of 60 now affected.2
The pathogenesis of AAA remains poorly understood,
however significant evidence has emerged in recent
years to suggest a chronic inflammatory process. In
particular, upregulation of cytokine pathways in asso-
ciation with increased matrix turnover by matrix met-
alloproteinases (MMPs) has been observed.3,4 Genetic
influences may play a crucial role in the regulation of
inflammatory responses.
There are several factors such as smoking, hyper-
tension, hypercholesterolaemia and male sex,5 which
are known to be significant risk factors for the
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agement of these co-morbidities and anti-smoking
campaigns attempt to address these factors, the
incidence of aneurysm continues to rise. This is in
contrast to other smoking related diseases such as
ischaemic heart disease, which have seen a fall in
incidence over a similar period.9 This has led to uncer-
tainty as to the significance of these factors in
aneurysm pathogenesis.
A positive family history of AAA in a first degree
relative is known to increase the risk of aortic aneu-
rysm by up to a factor of ten.10 There are different
theories which may explain this. Firstly, families are
likely to be subjected to similar environmental and so-
cioeconomic factors such as smoking habits, dietary
and exercise regimes, which may increase their risk
of AAA through the development of atherosclerotic
disease. However, in multivariate analysis accounting
for these factors, family history still appears to be a
significant and independent risk factor for AAA.5
This has led to investigation into the possibility of an
inheritable pattern of disease, possibly even a single
gene which predisposes to AAA formation.erved.
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component of aneurysm disease when he described
a family in whom three brothers were all affected by
AAA.11 Since then many familial studies have been
conducted in an attempt to establish a genetic link.
Several authors have also attempted to characterize
the mode of inheritance through segregation studies.
As the inflammatory process has been increasingly
implicated in AAA development, several studies have
begun to investigate specific inflammatory genes, of-
ten those which code for key proteins in the cytokine
cascade. This ‘candidate gene’ approach may provide
insight into individual susceptibility to AAA and also
advance understanding of the processes involved.
Methods
A search was conducted of the Medline and Ovid Em-
base databases from 1966 to the present day using the
search terms ‘abdominal aortic aneurysm’ and ‘gene’,
and these search results were then combined. This re-
sulted in 53 human publications limited to the English
language, of which 25 were felt to be relevant (i.e.
relating familial or genetic factors with AAA). These
papers were categorized according to their subject
and study design into familial, segregation or candi-
date gene studies. Relevant references were extracted
and collected manually. Papers were then reviewed
and summarized. The following review adheres to
the subheadings under which the publications were
collected.
Familial Studies
One of the earliest population based studies to exam-
ine the aetiology of AAA compared coronary heart
disease, stroke and aortic aneurysm.12 This was a pro-
spective study of mainly white races from over 1000
counties in the United States. There were approxi-
mately 500 000 females and 350 000 males who were
between 40 and 79 years old who were included in
the analysis. Subjects completed a questionnaire at en-
rolment, detailing significant co-morbidity and smok-
ing status, and were then followed up for 6 years. Any
deaths occurring during this period were classified by
the cause of death given on the death certificate. Dur-
ing the study, 431 men and 88 women died from aneu-
rysm related disease. The death rate from AAA was
found to be higher in men who were hypertensive.
This study found significant associations between in-
creased weight, low levels of exercise and smoking,
and the development of aortic aneurysm. Although
these common risk factors with coronary heart disease
are still thought to be significant today, Clifton’sEur J Vasc Endovasc Surg Vol 33, April 2007report of familial aneurysm in 1977 then provoked
a series of studies into a possible genetic cause for
aneurysms.
In 1986, Johansen and Koepsell compared the
family histories of 250 patients with AAA and 250
controls. They found that 19.2% of patients with an
aortic aneurysm reported having a first degree rela-
tive with a history of AAA. Only 2.4% of controls
reported a positive family history of AAA. They
therefore calculated an estimated relative risk of de-
veloping AAA if a first degree relative has already
been affected of 11.6.10 This represented a significant
clustering of AAA in families. In 1989 Darling and
Brewster conducted a study to determine if two dis-
tinct subtypes of aortic aneurysm may exist: familial
and non-familial. This was a nine year prospective
study of 542 consecutive patients undergoing abdomi-
nal aortic aneurysm repair. Eighty-two of these
patients reported a positive family history of AAA
in between two and five first degree relatives. Four
hundred and sixty patients therefore reported no pre-
vious incidence of aortic aneurysm in their family.
There were some initial differences observed between
the familial and non-familial groups. Firstly, the non-
familial group had a higher male preponderance of
AAA than the familial group (86% vs 65% male). Sec-
ondly, the mean age of the non-familial group tended
to be higher than that of the familial group (67.8 years
vs 62.4 years) and this difference was significant
among the male patients. The two groups were how-
ever comparable in terms of smoking status, and
number of patients affected by either hypertension
or diabetes. They also found no difference in aneu-
rysm morphology, either in terms of anatomy or aortic
wall composition, suggesting that although some
aneurysms may be the result of an unknown genetic
factor, the final pathological process is likely to be
similar to that in sporadic aortic aneurysm.13
A similar study conducted by Baird et al. in 1995
utilized ultrasound scanning to screen relatives of
both AAA patients and controls, in order to gain
a more reliable estimate of family tendency to aneu-
rysm development than relying solely on self reported
incidence (which inevitably will miss some affected
individuals). They recruited 126 unrelated patients
consecutively admitted to hospital with AAA and
100 healthy controls undergoing cataract surgery. All
of the controls, and 54 of the 427 siblings of aneurysm
patients, underwent ultrasound scan, and this data
was added to family history data obtained from inter-
views. They found that 4.4% of siblings of aneurysm
patients had an aneurysm versus 1.1% of controls on
the basis of family history alone. Following ultra-
sound scan, 19% of siblings of aneurysm patients
383The Genetic Basis of Abdominal Aortic Aneurysmswere found to have AAA versus 8% of controls. The
risk of aneurysm was shown to begin earlier and
increase more rapidly for siblings of affected individ-
uals compared with controls.14 Fitzgerald et al. agreed
with this finding, demonstrating 22% of male siblings
of AAA patients to have aneurysms on USS.15 The
familial trend observed in the incidence of AAA par-
ticularly among male relatives has led to suggestions
for targeted screening programmes for relatives of
affected individuals.16e18
Also in 1995, LaMorte et al. wrote the first report on
racial differences in rates of AAA repair. They ob-
served that atherosclerotic disease was more common
in black than white Americans, but aortic aneurysm
was more common in a white population. A multivar-
iate analysis comparing aneurysmal disease with
a control group (undergoing appendicectomy) con-
firmed hypertension, age and smoking as significant
risk factors for aneurysm disease, and reported a pro-
tective effect associated with diabetes. They found
black people to be at less risk of aneurysm than white
with an odds ratio of 0.29. They therefore concluded
that this observation may suggest the influence of
genetic factors.19
Two further studies in 1999 and 2000 confirmed the
increased incidence of AAA observed in first degree
relatives of affected individuals, and quantified the
odds ratios at 4.33 and 4.77 respectively.5,20
Although these observational studies have identi-
fied a clear familial tendency for aortic aneurysm
(see Table 1), most do not consider the effects of com-
mon familial factors such as socioeconomic status,
dietary and lifestyle considerations. Further studies
were therefore required to confirm and further inves-
tigate the genetic basis of AAA.
Segregation Studies
In view of the overwhelming evidence for a genetic
link, several studies have attempted to characterize
the pattern of inheritance of AAA. The earliest of
these was Tilson and Seashore in 1984 who studied50 families with clustering of AAA in 2 or more first
degree relatives. Following segregation analysis,
they concluded that if only one gene were responsible
for aortic aneurysm, it is likely to be autosomal, how-
ever they could not exclude multigene mechanisms.21
Powell and Greenhalgh in 1987 examined the fam-
ily histories of 60 consecutive patients undergoing
aneurysm repair. Of these, 20 patients had at least
one first degree relative with AAA. There were 320
first degree relatives and 192 siblings in total, and
they reported 25(8%) and 14(7%) aneurysms respec-
tively. They suggest that the genetic component of
aneurysm development is likely to contribute at least
70% of the overall susceptibility.22
Following on from this, Majumder et al. 1991 per-
formed a segregation analysis based on a population
of patients with ruptured and surgically treated aneu-
rysms. They found strong evidence to reject a sporadic
model of aneurysm development and found the mul-
tifactorial effect to be minimal. A major gene locus
was found to be likely and a recessive model was
shown to best fit their data.23
In contrast, Verloes in 1995 recruited 520 patients
treated for AAA at a single centre and studied the
276 patients who had a positive family history of an-
eurysm. Although they also strongly rejected a spo-
radic model, and also found no better fit with
a multifactorial model, a single dominant gene was
felt to give the best explanation of their findings. In
addition to this, they described an allele frequency
of 1:250 for the morbid allele, with a sex-dependent
penetrance which slowly increases with age to 0.3 in
women and 0.4 in men over the age of 80 years.24
This would go some way to explaining the far greater
incidence of aneurysms observed in men.
In 2003, Kuivaniemi et al. examined 233 families
known to have at least 2 members affected by AAA
from vascular centres in 7 different countries. They
agreed with the Majumder study on the whole,
reporting that the majority of their data fitted an auto-
somal recessive inheritance pattern. However, in
approximately 25% of cases, an autosomal dominant
pattern better explained their findings in agreementTable 1. Timeline of familial studies into aortic aneurysm
Year Author Number of Patients Study Design Ultrasound screening used? Incidence of AAA among
relatives (%)
1977 Clifton11 3 Observational No 3 brothers affected
in same family
1986 Johansen et al.10 250 Observational No 19.2%
1989 Darling et al.13 542 Observational No 15%
1995 Baird et al.14 126 Case control Yes 19%
1999 Salo et al.20 101 male relatives Case control Yes 11%
2000 Blanchard et al.5 98 Case control No Odds ratio of 4.77 if
relative affectedEur J Vasc Endovasc Surg Vol 33, April 2007
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lack of consistency in the mode of inheritance may be
indicative of multifactorial disease.25
In summary, there is overwhelming evidence of a
genetic predisposition to development of AAA shown
by clustering of aneurysms in families. Although no
clear pattern of inheritance has yet emerged, it is
generally agreed that an autosomal gene (or genes)
is the most likely, although both dominant and reces-
sive models may be feasible. Although studies have
suggested a single gene may be responsible, others
have suggested a multifactorial aetiology, and it is
likely that the interplay between genetic predisposi-
tion and environmental factors such as smoking and
hypertension are ultimately responsible for aneurys-
mal dilatation.
Candidate Genes
In order to further characterize the potential genetic
component of AAA pathogenesis, several investiga-
tors have adopted a ‘candidate gene’ approach. This
involves highlighting mechanisms involved in the in-
flammatory response and aneurysm formation, and
studying the genes coding for key enzymes. Many
of these genes have been shown to have polymorphic
sites which may in part explain the genetic predispo-
sition of some individuals, not just for aortic
aneurysms, but for a whole range of chronic inflam-
matory conditions.
Elastin and Elastases: MMP- 2, -7, -9 & -12
The degredation of medial elastin in the aortic wall
appears to be an initiating step in the process of aneu-
rysm formation. Matrix metalloproteinases (MMPs)
digest both collagen and elastin, however MMP-2,
-7, -9, and -12 are generally considered to be primarily
elastases. Elevated levels of these MMPs have been
shown to occur in aneurysmal aortic wall compared
with normal aorta.26
MMP-9, also referred to as gelatinaseB, is both a type
IV collagenase and elastase enzyme. A cytosine to thy-
midine substitution in position 1562 of the promoter
region of the MMP-9 gene produces a 1.5 fold increase
in promoter activity.27 It is therefore plausible that this
polymorphismmay be responsible for the upregulated
MMP-9 activity seen in association with AAA.
Jones et al. compared 414 patients with AAA, 172
patients with peripheral vascular disease, and 203
healthy controls with respect to the C-1562T polymor-
phism. They found a greater proportion of T allelesEur J Vasc Endovasc Surg Vol 33, April 2007amongst the aneurysm population than either of the
other groups, and quantified the odds ratio of devel-
oping AAA with this allele to be 2.41 in comparison
to the control group.27 However, other studies investi-
gating the effect of MMP-9 have found no significant
association between MMP-9 polymorphisms and
AAA.28,29 It may be that the increased MMP-9 levels
observed in the aneurysm wall are the result of in-
creased local stimulus, rather than a genetic predispo-
sition to MMP overproduction.
The MMP-12 gene has a polymorphic site in its pro-
moter region involving a single nucleotide transition
from Adenosine to Guanine in position -82. Human
studies of this gene polymorphism were initially con-
ducted in reference to aneurysmal coronary artery
disease, however the allele frequencies did not differ
significantly between the coronary aneurysm and con-
trol groups.30 Eriksson et al. later investigated the
genotype-phenotype relationships of MMP-12 in
addition to MMP-2, -3, and -9, and found no evidence
that any specific MMP polymorphism had a clinically
significant effect on aneurysm expansion,31 however
experimental studies have suggested a clear role for
MMP-12 in the development of aneurysms.32 There-
fore, although MMP-12 is likely to be involved in
aneurysm development, it is unlikely that the
polymorphic locus is responsible for the upregulation
seen.
There is a polymorphic site in the promoter region
of the MMP-2 gene with a cytosine to thymidine tran-
sition at the -1306 locus. Although this has not been
investigated with respect to aortic aneurysm disease,
it has been shown to be significant in the development
of coronary artery aneurysms, with patients affected
by aneurysm tending to have a higher proportion of
cytosine alleles than thymidine.30 This may be a poten-
tial area for further investigation.
Collagen and Collagenases: MMP-1, -8 & -13
Types I and III collagen are found in abundance in the
aortic wall and provide structural integrity and
strength. Defects in the collagen I gene are known to
cause problems such as Osteogenesis Imperfecta but
are not known to be associated with vascular
defects.26 In contrast with collagen I, alterations in
collagen III turnover are likely to be pivotal in the
weakening of the aortic wall and aneurysmal
dilatation.
Collagen III is secreted as a procollagen, and the
aminoterminal propeptide (PIIINP) is then cleaved
to produce the mature collagen molecule. The propep-
tide is detectable in the extracellular matrix following
385The Genetic Basis of Abdominal Aortic Aneurysmscleavage, and if collagen turnover increases rapidly,
large amounts of PIIINP are found. A study con-
ducted in 1995 by Satta et al. found significantly
higher levels of PIIINP in patients with AAA than
those with aorto-occlusive disease, indicating
increased collagen turnover.33 Anderson et al. also
described an increased collagen I to collagen III ratio
in a patient with multiple large vessel aneurysms.
They associated this with a polymorphism of the
collagen III gene resulting in an amino acid switch
from leucine to phenylalanine, which was present in
the patient, but absent in other asymptomatic family
members or control subjects.34 This has not been
further investigated by other authors.
Matrix metalloproteinases are largely responsible
for the alterations in matrix turnover seen in AAA.
Their activities are regulated at several levels: firstly
the transcription and translation of inactive precur-
sors (zymogens); secondly the post-translational acti-
vation of zymogens by proteolysis; and lastly by the
interaction of mature MMPs with their tissue inhibi-
tors (Tissue Inhibitors of MetalloProteinases, TIMPs).
Higashikata et al. used real-time reverse transcriptase
polymerase chain reaction (RT-PCR) to quantify gene
expression and found MMP-1 and -3 to be elevated in
aneurysmal compared with normal aorta.29 They also
found the ratio of MMP-1 to TIMP-1 and -3 was sig-
nificantly elevated, indicating increased tendency to
matrix degradation with decreased regulation by the
usual control mechanisms. These findings were previ-
ously reported by Tamarina et al. in 1997 when they
described elevated levels of MMP-1 mRNA and an in-
creased MMP-1 to TIMP-1 ratio.34 MMP-8 is a potent
type I collagenase, which has also been shown to be
upregulated in the aneurysm wall.35,36
To date, there is no clear evidence that the upregu-
lation of MMPs seen in association with AAA results
from a genetic predisposition. Although polymorphic
sites have been identified in the promoter regions of
several MMPs, no particular polymorphism has
been found with increased frequency in association
with aneurysmal disease. Although experimental
work with knockout mice has demonstrated a protec-
tive effect from complete lack of MMP-12, it is un-
likely that any naturally occurring polymorphism
would have such a dramatic effect on the gene func-
tion and consequent protection from AAA formation.
Tissue Inhibitors of MetalloProteinases
The balance between MMPs and their tissue inhibitors
(TIMPs) determines the composition of the extracellu-
lar matrix. There are currently four TIMPs which havebeen characterized and named TIMP-1 to -4. TIMP-1
is a specific inhibitor of MMP-1 and -9.
Tilson et al. in 1993 conducted a study to determine
whether the relative decrease in TIMP expression seen
in aneurysmal aorta occurs as a result of decreased tis-
sue expression or a primary genetic predisposition.
They found a point polymorphism from cytosine to
thymidine in the third position of codon 101, but dem-
onstrated that the amino acid for which it coded was
preserved. They also demonstrated normal fibroblast
expression of TIMP mRNA in association with this
polymorphism, and therefore concluded that there
was no evidence to suggest that the TIMP-1 deficiency
seen in aneurysmal aorta results from a primary gene
deficiency.37
More recently however, two studies have demon-
strated a significant difference in the allele frequencies
expressed in patients with AAA compared with con-
trol groups. Ogata et al. found an association between
the TIMP-1 polymorphism and AAA in male patients
without a family history of aneurysm,38 and Wang
et al. found a significant difference between aneu-
rysms and controls in the frequency of the TIMP-2
polymorphism, which occurs in the same position as
in the TIMP-1 gene, and is also a neutral polymor-
phism with no effect on translation.39
These single point polymorphisms do not affect the
amino acid sequence of the TIMP protein and there-
fore are unlikely to be significant in AAA pathogene-
sis, however other polymorphisms also exist. Several
novel single nucleotide polymorphisms of the TIMP-2
gene have been found including the -418 guanine to
cytosine locus, the -177 cytosine to thymidine locus
and the þ34 cytosine to adenosine locus. Whilst these
have not been investigated in relation to AAA, they
have been found to be linked and possibly significant
in relation to chronic obstructive pulmonary disease.40
It may be therefore, that although the single polymor-
phisms studied by Ogata and Wang are not in them-
selves responsible for the alteration in TIMP activity,
they may be markers for another polymorphism
which does affect translation.
Plaminogen Activator Inhibitor-1
Regulation of the MMP/TIMP system is partly con-
trolled by the plasmin system. The inactive pro-
enzyme of plasmin, plasminogen, is converted to its
active form by plasminogen activators, either tissue
type plasminogen activator (tPA) or urokinase plas-
minogen activator (uPA). Plasmin (the active enzyme)
in turn activates MMPs. The actions of plasminogenEur J Vasc Endovasc Surg Vol 33, April 2007
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inhibitors (PAI-1 and -2).
There is a polymorphism of the PAI-1 gene in posi-
tion -675 where the wild type gene has a 4G pattern,
but a 5G insertion may also be seen. The 4G allele
binds only an activator of transcription, whereas the
5G allele binds both an activator and a repressor,
and is therefore associated with relatively reduced
transcription of PAI-1.41 The frequency of the 5G allele
has been shown to be greatest among patients with
familial aneurysms at 53%, in comparison to 39%
in a control population and 38% in patients with
non-familial aneurysms.41
The 5G allele has also been analysed in relation to
aneurysm progression and patients homozygous for
the 5G insertion were found to have faster aneurysm
growth than those with a 4G allele.42
It is likely therefore, that the plasmin system may
be involved in progression of AAA and this makes
it a potential target for the development of medical
therapies to suppress aneurysm growth.
Interleukins
It is now generally accepted that AAA arises as a re-
sult of a chronic inflammatory process. Bown et al.
therefore studied a range of inflammatory cytokine
polymorphisms in relation to their prevalence in
AAA. Although polymorphisms of the interleukin
(IL)1b, IL-6, IL-10 and tumour necrosis factor alpha
(TNFa) genes were studied, only the IL-10 polymor-
phism appeared in higher frequency among aneu-
rysm patients than healthy controls.43 Interleukin-10
is an anti-inflammatory cytokine, and the -1082 poly-
morphism is associated with decreased IL-10 produc-
tion, thus limiting the ability of the subject to regulate
the inflammatory process which leads to AAA
formation.
Several other studies have confirmed the findings
of non-significant interleukin gene polymorphisms.
Marculescu et al. compared 135 patients with aneu-
rysms to 270 patients with coronary artery disease
with respect to six known polymorphisms in the IL-
1 gene. They found no significant differences in any
of the polymorphisms between groups and therefore
concluded no role for IL1 polymorphisms in the path-
ogenesis of AAA.44
Similarly, Jones et al. assessed the role of the -174G
to C substitution in polymorphic locus of the IL-6
gene. This is known to be a functionally significant
polymorphism as lower IL-6 levels have been re-
ported with the homozygous G genotype than when
a C allele is present. The authors found no linkEur J Vasc Endovasc Surg Vol 33, April 2007between IL-6 genotype and aneurysm progression,
however, the G allele did appear to be a predictor of
cardiovascular mortality.45
Angiotensin Converting Enzyme
The renin-angiotensin-aldosterone system plays a
major role in the conservation of salt and water and
as such is a useful therapeutic target for antihyperten-
sive agents. The angiotensin converting enzyme
(ACE) which converts angiotensin I into the active
angiotensin II has been shown to be highly expressed
in human aneurysmal aorta,46 and experimental stud-
ies have demonstrated that infusion of angiotensin II
produces large aortic aneurysms.47 This evidence is
suggestive that high local levels of angiotensin II may
play a significant role in AAA development.
There is a polymorphic site in the ACE gene which
consists of the presence or absence of a 287 base pair
DNA fragment corresponding to an alanine repetitive
sequence in the intron of the ACE gene. The polymor-
phism has been termed I for insertion of the fragment
and D for its deletion. The alleles are co-dominant
with an additive effect on plasma levels, so homozy-
gotes for the deletion allele have the highest plasma
levels of ACE and homozygotes for the insertion
have the lowest. Fatini et al. compared the genotypes
of 250 patients with AAA and 250 age and sex
matched controls. They found an increased D allele
frequency in the AAA group of 0.63 compared with
0.49 in the control group and this difference was
found to be highly significant.48
These findings were confirmed by Pola et al. They
segregated the aneurysm group into those with
hypertension and those without, in order to determine
whether the ACE polymorphism was acting via an
effect on blood pressure (which is already known to
predispose to aneurysm formation). Interestingly,
they found a high incidence of the DD genotype in nor-
motensive patients with aneurysms (70%), but only
32% of hypertensive patients with co-existent AAA
had this genotype. This does suggest that the polymor-
phism affects AAAdevelopment independently of any
association with blood pressure.49
In agreement with this finding, experimental stud-
ies have shown that whilst infusion of angiotensin II
produces AAA, infusion of incremental doses of aldo-
sterone produces no effect on aortic diameter.50 This is
significant as it suggests that the increased ACE
levels seen in the aneurysm wall may be stimulated
by a different pathway to the physiological renin-
angiotensin-aldosterone system.
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(ACEI) are already in routine clinical use in the treat-
ment of hypertension and are generally well tolerated,
studies into the effects of ACEI on aneurysms in
patients with differing ACE genotypes would be
interesting as this represents a potential therapeutic
target for futuremedical treatment of small aneurysms.
Methylene Tetra Hydro Folate Reductase
Homocysteine is a non-protein amino acid which is
involved in carbon metabolism and methylation reac-
tions. High plasma levels are toxic to vascular tissues,
and hyperhomocysteinaemia is known to be a risk
factor for early onset vascular disease.51 Excessive ho-
mocysteine is re-methylated by methionine synthase
and in this reaction, 5-methyltetrahydrofolate serves
as a methyl donor. This compound is produced by
methlyenetetrahydrofolate reductase (MTHFR) and
therefore a defect in this enzyme may lead to
hyperhomocysteinaemia.
There is a polymorphism in the MTHFR gene at the
677 locus which involves substitution of a cytosine
nucleotide for a thymidine. Strauss et al. demon-
strated an elevated T allele frequency amongst pa-
tients with AAA compared to a control group (0.37
vs 0.21) with an odds ratio for AAA of 4.4 if a T allele
was present.52 More recently, a large study of 428
patients with aneurysms failed to demonstrate an
association between the C677T polymorphism and
aneurysm formation, however they did demonstrate
significantly larger aneurysms amongst patients who
were homozygous for the T allele compared with
those who had a C allele.53
Platelet Activating Factor
Platelet activating factor (PAF) has been shown to in-
duce MMP-1, -2 and -9 in epithelial cells and fibro-
blasts.54,55 PAF is inactivated by the enzyme PAF
acetylehydrolase (PAF-AH). An autosomal recessive
inherited deficiency of PAF-AH has been reported in
the Japanese population,56 and this deficiency has
now been found to be the result of a single point mu-
tation (a guanine to thymidine substitution at position
994) in exon 9.57 With this polymorphism, heterozy-
gotes show reduced enzymatic activity and homozy-
gotes have no PAF-AH activity at all.
Unno et al. conducted a case control study to deter-
mine the effect of the PAF-AH polymorphism on
AAA. They found a higher proportion of T alleles
among the aneurysm group, and the risk ofdeveloping an aneurysm if a T allele was present
was 2.48.58 They also quantified enzyme activity and
found it to be much greater in homozygous GG pa-
tients with an aneurysm than those without, confirm-
ing that the enzyme is likely to be involved in AAA
development.
Nitric Oxide Synthase
Nitric oxide (NO) is responsible for most vasodilata-
tion induced by the endothelium and a decrease in
NO production may cause abnormal vascular func-
tion. NO is produced by endothelial NO synthase
(eNOS), the gene coding for which is located on chro-
mosome 7. A 27 base pair repeat is present in intron 4
of the eNOS gene and it is possible that this polymor-
phism may affect function of the enzyme. Kotani et al.
studied an aneurysm and a control group, dividing
the aneurysm group into surgical and non-surgical
patients. They found that 10% of the control group
had 4 repeats present compared to 14% of the aneu-
rysm group. The remainder in each group had 5 re-
peats at the polymorphic site. When the aneurysm
group was subdivided, 21% of the surgical patients
were found to have 4 repeats in contrast to only 4%
of the non-surgical group, and the authors conclude
that the 4 repeat genotype may be associated with
rapid progression of AAA.59
Two further polymorphisms of the eNOS gene
have been described: a T substitution to C at the
-786 locus and a G substitution to T at the 894 locus.
Although a significant association has been found
between the G894T allele and AAA, no such link
was demonstrated for the T786C allele.60
Human Leucocyte Antigens
The Human Leukocyte Antigen (HLA) system is a rec-
ognition system which controls a variety of cell-cell
interactions. Although not directly part of the inflam-
matory response, it determines T cell function, which
is in turn central to chronic inflammatory processes.
There are two arms to the HLA system: HLA class I
which comprises HLA-A and eB molecules and is
recognized by receptors on CD8 positive cells (sup-
pressor T cells); and HLA class II (HLA-DR) which
are recognized by receptors on CD4 positive T helper
cells. Certain HLA subtypes have been associated
with a number of chronic inflammatory conditions,
and represent the genetic basis of a number of well
known diseases such as diabetes and rheumatoid
arthritis.61Eur J Vasc Endovasc Surg Vol 33, April 2007
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aneurysm. Rasmussen et al. studies the HLA-DR B1
locus which has 12 associated alleles. They found
B1*02 and B1*04 subtypes to be more common
amongst the aneurysm group compared to a control
group, and the B1*01, B1*08 and B1*14 alleles to be
more frequent among the controls.62 These findings
were confirmed by Monux et al. whose results
did not reach statistical significance, but suggested
HLA-DR B1*01 to be protective and HLA-DR B1*04
to predispose to AAA.63 Increased frequency of the
HLA-DR2(15) allele has also been described amongst
aneurysm patients compared with controls (58.7% vs
28%) in a Japanese population.64
Class I HLA antigens may also be significant, and
a case control study found HLA-A2 to be present in
60.4% of patients with aneurysms but only 42.6% of
controls (P¼ 0.036); and HLA-B61 to be present in
30.4% of patients with aneurysms but only 11.4% of
controls (P¼ 0.002).65
Although the precise mechanism by which HLA
genotype affects individual susceptibility is not yet
fully understood and is likely to be a complex inter-
play between genetic predisposition and environmen-
tal exposure, it may be possible to identify an HLA
allele, or combination of alleles, which function as
a genetic marker for AAA.
Inflammatory Receptors: CCR2 and CCR5
Many inflammatory cytokines have cell signaling or
chemotactic properties and attract inflammatory cells
to the site of injury. This family of cytokines are often
termed chemokines and share a common C-C
structure. Many chemokines, such as monocyte
chemoattractant protein 2 (MCP-2), macrophage
inflammatory protein 1 alpha (MIP-1a) and beta
(MIP-1b), and Regulated on Activation Normal T
cell Expressed and Secreted protein (RANTES), effect
their function through ligand binding with a C-C
chemokine receptor.
Chemokine receptors have attracted much scien-
tific interest in recent years as they function as a co-
receptor for the Human ImmunoDeficiency Virus
(HIV) into CD4 positive cells and anti-chemokine
receptor therapies are being trialed in this context.
As they are central to cell signaling and the inflamma-
tory process, CCR (C-C chemokine receptors) have
also been studied with respect to their potential role
in chronic inflammatory conditions including AAA.
There are two chemokine receptors in particular,
CCR2 and CCR5, which are structurally similar
to one another and are known to have geneEur J Vasc Endovasc Surg Vol 33, April 2007polymorphisms which affect protein translation.66
Studies of these polymorphisms in relation to HIV
susceptibility have demonstrated a relative resistance
amongst patients who are homozygous for the poly-
morphic alleles compared to those who have a wild
type gene.67
CCR5 has a 32 base pair deletion (D32) polymor-
phism in the promoter region of the gene. This results
in a frameshift and premature termination of the pro-
tein.68 The role of this polymorphism in susceptibility
to AAA has been investigated, and a higher incidence
of the D32 allele was observed among patients with
aneurysms than patients with other vascular patho-
logy (carotid stenosis and peripheral vascular disease)
or healthy controls.69 Further understanding of the
role of chemokine receptors in AAA may provide
a potential target for modulation of the inflammatory
response through the development of agents to block
these receptors.
Conclusion
Although there is overwhelming evidence for a ge-
netic predisposition to AAA formation demonstrated
by both familial and segregation observational
studies, no single gene has yet emerged as the key
to understanding this relationship. Cytokine path-
ways are extremely complex, and the regulation of
this system may underlie the development of AAA.
Many of the cytokine genes contain polymorphic
loci, and although significant associations have been
found between certain gene polymorphisms and
AAA, it is unlikely that any one single gene will
emerge as a critical factor. It is likely that downregula-
tion of any particular cytokine or pathway due to a
genetic polymorphism will be counterbalanced by
upregulation of a similar pathway to compensate.
As such, it may be that a particular combination of
polymorphisms predisposes to AAA formation, but
any individual gene has a limited effect.
The role of hypertension, smoking and male sex
must also be taken into consideration as the evidence
supporting involvement of these risk factors is over-
whelming. It is likely that the true mechanism under-
lying aneurysm formation will involve the interplay
between a genetic predisposition and environmental
risk factors such as these.
Understanding the genetic predisposition to AAA
development will provide a greater understanding
of the condition as a whole and may provide potential
targets for therapeutic intervention to modulate the
inflammatory response. Although the candidate
gene approach has led to significant advances in
389The Genetic Basis of Abdominal Aortic Aneurysmsunderstanding the pathogenesis of AAA, it is unlikely
that a single gene polymorphism will hold the key to
aneurysm formation. Whole genome studies are likely
to be required in order to fully understand the patho-
genesis of abdominal aortic aneurysm.
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